# OK432 (Picibanil) in the Treatment of Lymphatic Malformations

> **NCT03427619** · PHASE2 · COMPLETED · sponsor: **Richard JH Smith** · enrollment: 275 (actual)

## Conditions studied

- Lymphatic Malformations

## Interventions

- **DRUG:** OK432

## Key facts

- **NCT ID:** NCT03427619
- **Lead sponsor:** Richard JH Smith
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10-05
- **Primary completion:** 2018-04-30
- **Final completion:** 2018-04-30
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2021-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03427619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03427619, "OK432 (Picibanil) in the Treatment of Lymphatic Malformations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03427619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*